MRK · Merck & Co., Inc.

Track MRK — free

$144.30 +0.49 (+0.34%) At close · Oct 2

S&P 500 member Russell 1000 member Dow 30 member Rebalance outlook locked

Market Cap

$367.07B

2.47B

Volume · Oct 2 9.66M Avg daily vol (3M) 9.83M

Up next

Next earnings call

Nov 7, 2026 Est · unconfirmed · in 5 wks

Latest filing: 10-Q

filed Aug 7, 2026

Q2 2026 earnings call transcript

call held Aug 4, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$66.57B

Trailing 12 months

Net income (TTM)

$3.17B

Trailing 12 months

Revenue growth YoY

+5.1%

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

115.4

Trailing earnings · reciprocal yield 0.9%

FCF yield

4.4%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

−$46.77B

Latest balance sheet

Dividend yield

2.4%

Trailing 12 months

Shares change YoY

-1.7%

Year over year · fewer shares

Price change (1Y)

+61.2%

Trailing year

Short interest

1.4%

Latest settlement · 4.2 days to cover

View all 115 metrics

Equibles Research

our published analysis of this company

Research Thesis July 31, 2026

Novo Nordisk's 1.3 million Wegovy pill TRxs meet a 50% WAC cut — and the bear case still wins

Novo Nordisk is the only name in the GLP-1 bellwether set guiding negative adjusted-sales growth for 2026 (-4% to -12% at CER), even as Wegovy pill TRxs hit around 1.3 million in Q1 2026 and the 1 January 2027 WAC reset to USD 675 locks in further realised-price compression.

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Neutral Momentum Strong Sentiment Bearish Fundamentals Strong Quant / Vol Low

Market backdrop VIX 15.3 · calm Equity put/call 0.58

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +17%

above

Price vs 50-day avg +1%

above

RSI (14) 46

neutral

MACD trend Negative

52-week position 84%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Strong

1-month return −5%

trailing

6-month return +20%

trailing

YTD return +37%

this year

Relative strength +8%

vs S&P · 6-mo

Sentiment

smart money

Bearish

Trend (MA cross) No cross

50d $142 › 200d $123 — 50d above 200d

Institutional flow Distributing

20 of 3,863 funds reported for Sep 30 · net -60.8K sh shares · +1 new

Insider flow Distributing

Net -$30.0M over 90 days · 100% sells

Short interest Rising

1.40% of float · ▲ +13.7% MoM · 4.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

3,863 holders — near 3-yr high, broad support

Squeeze score 59

elevated · 0–100

Fundamentals

Strong

Revenue growth +1%

Y/Y

EPS growth +8%

Y/Y

Free cash flow $12.4B

Valuation P/E 119

rich

Buyback $5.7B

remaining

Balance sheet $17.1B

net debt

Quant / Vol

risk profile

Low

Volatility 29%

annualized · 1-yr

Max drawdown −12%

past year

ATR 2.4%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 3 of last 5

Latest guidance · from the 8-K filed Aug 4, 2026

Non-GAAP Gross margin · Full Year 2026 Non-GAAP Initiated 81%

Guided vs delivered · last 5 settled

Worldwide Sales Full Year 2024

guided $62.7B – $64.2B

guided $62.7B – $64.2B $64.17B In line

Worldwide sales Full Year 2023

guided $59.7B – $60.2B

guided $59.7B – $60.2B $60.12B In line

GAAP EPS Full-Year 2023

guided $5.85 – $5.97

guided $5.85 – $5.97 $0.14 Miss −97.6%

Total revenues 2021

guided $46.4B – $47.4B

guided $46.4B – $47.4B $48.7B Beat +3.8%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral

1 · 4 · 2

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+17% Bullish

Price vs 50-day avg

+1% Bullish

RSI (14)

46 Neutral

MACD trend

Negative Bearish

52-week position

84% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bearish · 3 of 6

Trend (MA cross) No cross

50d $142 › 200d $123 — 50d above 200d

Institutional flow Distributing

20 of 3,863 funds reported for Sep 30 · net -60.8K sh shares · +1 new

Insider flow Distributing

Net -$30.0M over 90 days · 100% sells

Short interest Rising

1.40% of float · ▲ +13.7% MoM · 4.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

3,863 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $82 Now $144 · 84% Range high $156

vs 200-day avg +17% vs 50-day avg +1%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Alliance Revenue - Koselugo	$10M	the three months ended June 30, 2026 filing	—
Alliance Revenue - Lynparza	$365M	the three months ended June 30, 2026 filing	-1.4%

Alliance Revenue - Reblozyl	$122M	the three months ended June 30, 2026 filing	+14.0%

Capvaxive sales	$184M	the three months ended June 30, 2026 filing	+42.6%

Gardasil/Gardasil 9 sales	$1.17B	the three months ended June 30, 2026 filing	+3.8%

Gross margin	73.5%	second quarter of 2026 filing	—
International sales	$7.24B	the three months ended June 30, 2026 filing	—
Keytruda/Keytruda Qlex sales	$8.37B	the three months ended June 30, 2026 filing	—
M-M-R II sales	$96M	the three months ended June 30, 2026 filing	—
Non-GAAP EPS assuming dilution non-GAAP	-$0.13	the three months ended June 30, 2026 filing	—
GAAP → non-GAAP reconciliation GAAP EPS assuming dilution as reported under GAAP -$0.54 +$0.41 EPS difference = Non-GAAP EPS assuming dilution -$0.13
Non-GAAP income (loss) before taxes non-GAAP	$550M	the three months ended June 30, 2026 filing	—
GAAP → non-GAAP reconciliation GAAP (Loss) income before taxes as reported under GAAP -$683M +$1.09B Acquisition- and divestiture-related costs +$334M Restructuring costs -$191M Income from investments in equity securities, net = Non-GAAP income (loss) before taxes $550M
Non-GAAP net (loss) income attributable to Merck & Co., Inc. non-GAAP	-$330M	the three months ended June 30, 2026 filing	—
ProQuad sales	$235M	the three months ended June 30, 2026 filing	—
Sales of the Bravecto (fluralaner) line of products	$359M	second quarter of 2026 filing	—
U.S. sales	$9.37B	the three months ended June 30, 2026 filing	—
Varivax sales	$260M	the three months ended June 30, 2026 filing	—
Vaxneuvance sales	$148M	the three months ended June 30, 2026 filing	-35.4%

Welireg sales	$271M	the three months ended June 30, 2026 filing	+67.3%

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - General — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
MRK Merck & Co., Inc. this stock	$367.07B	+37.1%	+1.3%	119.0	1.4%
LLY ELI LILLY & Co	$1.11T	+6.3%	+44.7%	39.7	0.8%
JNJ Johnson & Johnson	$653.61B	+23.7%	+6.0%	31.5	0.9%
ABBV AbbVie Inc.	$466.80B	+15.0%	+8.6%	74.6	1.1%
NVS Novartis AG	$276.48B	+2.3%	—	—	0.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

3,864

% held: 82.0%
Reported: 20 of 3,863
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

1,629

View

Short & Settlement

Short Interest Rising

Shares short

34.4M

Days to cover: 4.2d
Change: +4.1M sh

View

Short Volume

Short vol %

33%

As of: Oct 2, 2026

Short Total

View

Fails to Deliver

FTD shares

5.1K

Value: $727.1K
As of: Sep 14, 2026

View

Off-Exchange

Off-exchange %

47.0%

Week of: Aug 24, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$30.0M

Buyers / Sellers: 0 / 5

Buyers Sellers

View

Congressional Trades Sell

Member

Alan Armstrong

Amount: $15.0K–$50.0K
Traded: Mar 27, 2026

View

Financials

Revenue (FY)

$65.0B

Net income (FY): $18.3B
EPS diluted: $7.28

View

Buybacks

Authorized

$10.0B

Remaining: $5.7B

Spent Remaining

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Sep 14, 2026
This year: 15

View

Proposed Sales

Value

$1.4M

Shares: 10.0K
Filed: Aug 13, 2026

View

Earnings & Events

Webcasts

Last webcast

Sep 14, 2026

View

Performance

	5D	20D	120D	MTD	YTD
MRK	-3.0%	-5.3%	+20.1%	-0.7%	+37.1%
SPY	-0.2%	-0.5%	+12.2%	+0.9%	+12.9%
vs SPY	-2.8%	-4.8%	+7.9%	-1.6%	+24.2%

Capital returns

Latest dividend

$0.85 / share · ex Sep 15, 2026

Raised 4.9%

Paid (TTM)

$3.40 / share · 4 payouts

Dividend yield (TTM, derived)

2.36%

Buyback program · as of Jun 30, 2026

Authorized

$10.00B

Spent (derived)

$4.30B

Remaining

$5.70B

Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 310158 CUSIP 58933Y105 13F (30d) 110 filings 55 filers Visit website Investor relations

MRK · Merck & Co., Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Research

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance

Capital returns